When is active surveillance the appropriate treatment for prostate cancer?

By Albertsen Peter C.  

Acta Oncologica, Vol. 50, Iss. 1, 2011-06 ,pp. : 120-126

Informa Healthcare

Access to resources Recommend Favorite

Target Practice: Figuring Out Which, When, and Why to Use Systemic Therapies for Metastatic Colon Cancer

By Holen Kyle  

Cancer Investigation, Vol. 24, Iss. 1, 2006-03 ,pp. : 98-105

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when

By Olver Ian N  

Future Oncology, Vol. 4, Iss. 1, 2008-02 ,pp. : 125-131

Future Medicine

Access to resources Recommend Favorite

Quality of Local Treatment or Biology of the Tumor: Which are the Trump Cards for Loco-regional Control of Retroperitoneal Sarcoma?

By Gronchi Alessandro  

Annals of Surgical Oncology, Vol. 20, Iss. 7, 2013-07 ,pp. : 2111-2113

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome

By Wang Hao   Song Shuichuan   Kou Geng   Li Bohua   Zhang Dapeng   Hou Sheng   Qian Weizhu   Dai Jianxin   Tian Liang   Zhao Jian   Guo Yajun  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 11, 2007-11 ,pp. : 1775-1783

Springer Publishing Company

Access to resources Recommend Favorite